tuneTypical Dose
1,000-1,500 mg per day (divided into 2-3 doses)
Botanical Derived
Berberine
Berberine (isoquinoline alkaloid from Berberis, Coptis, Hydrastis)
Evidence TierAWADA NOT PROHIBITED
watchEffect Window
2-4 weeks for glucose changes. 8-12 weeks for HbA1c and lipid panel shifts.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Berberine is a plant alkaloid that affects glucose and lipid metabolism through AMPK-related pathways and gut signaling. It is used for blood sugar and cardiometabolic support.
Randomized trials and meta-analyses show improvements in fasting glucose, HbA1c, triglycerides, and LDL cholesterol, especially in insulin-resistant or metabolic-syndrome populations. More recent synthesis also supports improved insulin resistance and some lipid and androgen markers in polycystic ovary syndrome, though fertility outcomes remain less certain. Minority benefits include modest weight loss and gut microbiome changes. Gastrointestinal side effects are common and can limit practical benefit.
Activates AMPK to increase glucose uptake and improve insulin sensitivity. Inhibits PCSK9 to lower LDL cholesterol. Modulates gut microbiome composition.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduces fasting blood glucose by ~0.9 mmol/L
- Reduces HbA1c by ~0.7%
- Lowers LDL cholesterol and triglycerides
Secondary Outcomes
- Improves HOMA-IR in metabolic syndrome
- Improves PCOS symptoms
Safety
Contraindications and Interactions
Contraindications
- Pregnancy (avoid due to uterotonic potential, placental transfer, kernicterus risk in newborns)
- Breastfeeding/lactation
- Neonates and children
Side effects
- Abdominal/stomach pain (often dose-limiting when taken as a single large bolus)
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Flatulence
- Dizziness
- Drowsiness
Interactions
- Metformin and other blood-glucose-lowering drugs (Probable/Moderate) - Additive glucose-lowering effects may increase hypoglycemia risk.
- Cyclosporine (Probable/Major) - CYP3A4 and P-glycoprotein inhibition may increase cyclosporine exposure.
- Macrolide antibiotics (Possible/Moderate) - Potential for altered exposure via shared CYP/P-glycoprotein pathways.
- Anticoagulants (Possible/Moderate) - Monitor for enhanced effects and bleeding risk with co-use.
- Drugs that are CYP3A4 substrates (Probable/Moderate) - Berberine can inhibit CYP3A4, which could reduce the metabolism of CYP3A4 substrates, potentially increasing their levels and effects.
- Drugs that are CYP2D6 substrates (Possible/Moderate) - Berberine may inhibit CYP2D6, which could reduce the metabolism of CYP2D6 substrates, potentially increasing their levels and effects.
- Drugs that are CYP2C9 substrates (Possible/Unknown) - Berberine may inhibit CYP2C9, which could reduce the metabolism of CYP2C9 substrates, potentially increasing their levels and effects.
- Blood-pressure-lowering drugs (Possible/Moderate) - Berberine may have additive blood-pressure-lowering effects with medications that lower blood pressure.
- Supplements that are CYP3A4 substrates (Probable/Unknown) - Berberine can inhibit CYP3A4, which could reduce the metabolism of supplements that are CYP3A4 substrates, potentially increasing their levels and effects.
- Supplements that are CYP2D6 substrates (Possible/Unknown) - Berberine may inhibit CYP2D6, which could reduce the metabolism of supplements that are CYP2D6 substrates, potentially increasing their levels and effects.
- Supplements that are CYP2C9 substrates (Possible/Unknown) - Berberine may inhibit CYP2C9, which could reduce the metabolism of supplements that are CYP2C9 substrates, potentially increasing their levels and effects.
Avoid if
- Pregnant people
- Breastfeeding/lactating people
- Neonates and children
- People using cyclosporine without medical supervision
- People using blood-glucose-lowering drugs without monitoring
- People using blood-pressure-lowering drugs without monitoring
- People using drugs that are cyp3a4 substrates
- People using drugs that are cyp2d6 substrates
- People using supplements that are cyp3a4 substrates
Evidence
Study-level References
berberine-SRC-001RCT
Sourceopen_in_newYin J, et al. "Efficacy of berberine in patients with type 2 diabetes mellitus." Metabolism. 2008;57(5):712-717.
Population: 116 adults with type 2 diabetes
Dose protocol: 500mg three times daily for 3 months
Key findings: Berberine significantly decreased HbA1c by 0.9%, fasting blood glucose, postprandial blood glucose, and triglycerides. Hypoglycemic effect was comparable to metformin in head-to-head comparison.
Paper content
Berberine significantly decreased HbA1c by 0.9%, fasting blood glucose, postprandial blood glucose, and triglycerides. Hypoglycemic effect was comparable to metformin in head-to-head comparison.
berberine-SRC-002Systematic review and meta-analysis
Sourceopen_in_newDong H, et al. "Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis." Evid Based Complement Alternat Med. 2012;2012:591654.
Population: 14 RCTs, 1,068 participants with T2DM
Dose protocol: 0.5-1.5g/day, 8-24 weeks
Key findings: Berberine combined with lifestyle intervention significantly reduced HbA1c, fasting glucose, and triglycerides vs lifestyle alone. Effect size for glucose-lowering was comparable to oral hypoglycemic agents.
Paper content
Berberine combined with lifestyle intervention significantly reduced HbA1c, fasting glucose, and triglycerides vs lifestyle alone. Effect size for glucose-lowering was comparable to oral hypoglycemic agents.
berberine-SRC-003Systematic review and meta-analysis
Sourceopen_in_newLiang Y, et al. "Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis." Endocr J. 2019;66(1):51-63.
Population: 28 RCTs, 2,569 participants
Dose protocol: 0.6-2.7g/day, 4-24 weeks
Key findings: Confirmed berberine reduces fasting glucose (WMD -0.87 mmol/L), HbA1c (WMD -0.72%), triglycerides, and total cholesterol vs placebo. GI adverse events were the most common side effect. Most included trials were Chinese with moderate methodological quality.
Paper content
Confirmed berberine reduces fasting glucose (WMD -0.87 mmol/L), HbA1c (WMD -0.72%), triglycerides, and total cholesterol vs placebo. GI adverse events were the most common side effect. Most included trials were Chinese with moderate methodological quality.
berberine-SRC-004Systematic review and meta-analysis
Sourceopen_in_newBerberine for polycystic ovary syndrome: systematic review and meta-analysis. Reproductive Biomedicine Online. 2024. PMID:39197884.
Population: Women with polycystic ovary syndrome across randomized and controlled clinical trials.
Dose protocol: Most included PCOS trials used berberine 500 mg two to three times daily for 8-16 weeks.
Key findings: Meta-analysis found improvements in insulin resistance and some lipid and androgen markers in women with PCOS, while reproductive outcomes remained less consistent across trials.
Notes: Comparator mix and small individual trials limit precision.
Paper content
Meta-analysis supported improvement in insulin resistance and some lipid and androgen markers in women with PCOS, while reproductive outcomes remained less consistent.
berberine-SRC-005Systematic review and meta-analysis
Sourceopen_in_newHa S, Song X. Berberine as adjuvant therapy for treating reduced fertility potential in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials. Explore (NY). 2024;20(6):103040. doi:10.1016/j.explore.2024.103040. PMID:39236662.
Population: Infertile women with polycystic ovary syndrome or insulin resistance undergoing assisted reproduction.
Dose protocol: Berberine-containing fertility protocols varied across included assisted-reproduction studies.
Key findings: Review suggested possible benefit for selected assisted-reproduction outcomes in infertile women with PCOS or insulin resistance, but the evidence base remained small and setting-specific.
Notes: Useful for narrowing the fertility wording. Not a stand-alone reason to recommend berberine for all PCOS cases.
Paper content
Meta-analysis suggested berberine can improve some assisted-reproduction outcomes in women with PCOS or insulin resistance, but the evidence base remains comparator-specific and relatively small.
berberine-SRC-006Systematic review and meta-analysis of randomized placebo-controlled trials
Sourceopen_in_newLiu D, Zhao H, Zhang Y, Hu J, Xu H. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Front Pharmacol. 2025;16:1572197. doi:10.3389/fphar.2025.1572197. PMID:40740996.
Population: Adults with metabolic syndrome or related metabolic abnormalities across randomized placebo-controlled berberine trials.
Dose protocol: Placebo-controlled berberine protocols varied across metabolic syndrome trials.
Key findings: Updated placebo-controlled meta-analysis supported reductions in fasting glucose, triglycerides, waist circumference, and LDL cholesterol, with no clear blood-pressure effect.
Notes: This is a better anchor for current wording than older equivalence-style comparisons with diabetes medications.
Paper content
This placebo-controlled meta-analysis is a useful modern anchor because it avoids most of the interpretive noise introduced by active-comparator and lifestyle-only designs. Berberine improved fasting glucose, triglycerides, waist circumference, LDL cholesterol, total cholesterol, BMI, and 2-hour glucose tolerance, while blood-pressure and HDL effects were not significant. The study supports a real cardiometabolic effect, but not a broad claim that berberine improves every metabolic-syndrome component.
berberine-SRC-007Multicenter, randomized, double-blind, placebo-controlled trial
Sourceopen_in_newZhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020;11(1):5015. doi:10.1038/s41467-020-18414-8. PMID:33024120.
Population: Newly diagnosed, treatment-naive adults with type 2 diabetes across 20 centers in China.
Dose protocol: Berberine 600 mg twice daily for 12 weeks in a 4-arm RCT (n=409) with gentamicin pretreatment.
Key findings: Both berberine-alone and probiotics-plus-berberine groups significantly reduced HbA1c versus placebo (P<0.001). Metagenomic analysis showed berberine modulated gut microbiome through bile acid metabolism via Ruminococcus bromii.
Notes: The PREMOTE study is the largest and best-designed berberine RCT to date, published in Nature Communications.
Paper content
The PREMOTE study was a large multicenter RCT in 409 newly diagnosed type 2 diabetes patients randomized to berberine, probiotics, their combination, or placebo for 12 weeks. Both the berberine-alone and combination groups achieved significantly greater HbA1c reductions than placebo. Metagenomic analysis revealed that berberine modulated the gut microbiome by inhibiting deoxycholic acid biotransformation through Ruminococcus bromii, providing a mechanistic link between berberine, the gut microbiome, and its antidiabetic effects.
berberine-SRC-008Randomized, double-blind, placebo-controlled trial
Sourceopen_in_newKoperska A, Moszak M, Seraszek-Jaros A, Bogdanski P, Szulinska M. Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial. J Physiol Pharmacol. 2024;75(3). doi:10.26402/jpp.2024.3.06. PMID:39042390.
Population: Adults with metabolic dysfunction-associated fatty liver disease (MAFLD).
Dose protocol: Berberine 1500 mg per day for 12 weeks versus placebo in 70 adults with MAFLD.
Key findings: Significantly improved ALT, De Ritis ratio, and total cholesterol versus placebo. BMI changes correlated with liver enzyme and insulin resistance improvements.
Notes: First RCT specifically targeting MAFLD with berberine, extending the hepatic evidence beyond metabolic syndrome framing.
Paper content
This 12-week double-blind placebo-controlled trial in 70 adults with metabolic dysfunction-associated fatty liver disease found that berberine 1500 mg per day significantly improved liver enzymes (ALT, De Ritis ratio) and total cholesterol compared with placebo. Both groups showed trunk fat reduction. BMI changes in the berberine group correlated with improvements in ALT, AST, fatty liver index, and insulin resistance markers.